We're keeping Eyes On Diabesity. With new approvals, data on the horizon, and M&A to bolster pipelines, it seems like there's something new everyday. Here we cover new MACE indications and the Metsera bidding war. What were you watching?

We've had Eyes on the MASH activities, and the latest M&A between Novo Nordisk and Akero Therapeutics caught our eye. In IPF, Boehringer's newly approved Jascayde...

Lately we've had Eyes On: Clinical Data, FDA news, M&A, and more. Read more about uniQure's AMT-130 data for Huntington's Disease, Roche's acquisition of 89bio for MASH, JnJ's Iconic Advance Data for Psoriasis, Lundbeck's CRL letter for PTSD, and the latest buzz around acetaminophen.

🆕 Introducing AI-Powered Insights in PharmaTell Studio. With the launch of our brand-new “Eyes on Pharma: AI Summary” feature, we’re adding artificial intelligence (AI) to the core of the PharmaTell experience helping our users find relevant insights faster than ever before.

This week we've had Eyes On Commercial Development and the FDA. Several companies have announced partnerships / acquisitions to further boost their pipelines and strengthen their competitive advantage.

This week we've had Eyes On BioPharma updates and US Regulatory moves on EU Tariffs. Check out Lilly 's data and expectations for Verzenio, GSK's deal with Hengrui, Novo Nordisk & Replicate Therapeutics agreement on sRNA, and the latest on US-EU Pharma tariffs.